Quarterly report pursuant to Section 13 or 15(d)

Debt and Interest- Additional Information (Detail)

v3.8.0.1
Debt and Interest- Additional Information (Detail) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Mar. 12, 2018
Mar. 31, 2018
Dec. 31, 2017
Opus Credit Facility [Member]      
Debt [Line Items]      
Debt Instrument, Interest Rate, Stated Percentage   12.00%  
Debt instrument Expiration Period Sep. 14, 2019   Sep. 14, 2018
Venture Notes [Member]      
Debt [Line Items]      
Debt Instrument, Interest Rate, Stated Percentage   8.00%  
Debt Instrument, Face Amount   $ 21.7  
Debt Instrument, Term   36 months  
Debt Instrument, Maturity Date, Description   The notes mature in 36 months from issuance, provided that during the first 24 months the Company may extend the maturity date by six months.  
NSC [Member] | Venture Notes [Member]      
Debt [Line Items]      
Warrant On Sale Price Of Note Percentage   25.00%  
Payments of Financing Costs   $ 1.7  
Class of Warrant or Right, Expiration Period   10 years  
Aevitas Therapeutics, Inc [Member] | Venture Notes [Member]      
Debt [Line Items]      
Proceeds from Notes Payable   $ 1.4  
Tamid Bio, Inc [Member] | Venture Notes [Member]      
Debt [Line Items]      
Proceeds from Notes Payable   1.0  
Cellvation [Member] | Venture Notes [Member]      
Debt [Line Items]      
Proceeds from Notes Payable   $ 0.4